title: Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes.
abstract: BACKGROUND
  In primary aldosteronism (PA), lateralized aldosterone excess can be treated with aldosterone antagonists or surgery, which raises the question as to whether surgery or medications should be the preferred management. A difference in required patient follow-up/clinic resource utilization might provide a surrogate estimate of the comparative outcome efficacy of medical versus surgical therapy.
  
  
  METHODS
  From a retrospective review of our adrenal vein sampling (AVS) database June 2005 to August 2011, we chose all patients with PA who were surgical candidates and investigated with AVS. There were 77 subjects; 38 (with aldosteronoma) had unilateral adrenalectomy, and 39 (7 aldosteronoma and 32 hyperplasia) were treated with primary medical therapy. After AVS, patients with nonsurgical disease immediately started mineralocorticoid antagonists and follow-up measured from the AVS date. Surgical patients were seen in the clinic immediately after hospital discharge and follow-up measured from the operative date. Target BP was <140/90 before discharge to the community.
  
  
  RESULTS
  Total follow-up ranged from 1 to 55 months, and 4 subjects were lost to follow-up. Mean follow-up in the medical and surgical groups was 13.4 versus 6.5 months (p < 0.004). There was a trend toward more clinic visits for the medical group (7.0 vs 5.2, p = 0.17).
  
  
  CONCLUSIONS
  Most PA patients can be managed by medical or surgical approaches. Medically treated patients require much longer-term follow-up to manage their condition, whereas most surgical patients can be successfully discharged shortly after surgery. When possible, surgical management may represent a more expeditious means of treating PA.
authors.affiliation: Division of Endocrinology, Faculty of Medicine, University of Calgary, Calgary, AB, Canada. gregory.kline@albertahealthservices.ca
authors.forename: G A
authors.initials: GA
authors.lastname: Kline
authors.forename: J L
authors.initials: JL
authors.lastname: Pasieka
authors.forename: A
authors.initials: A
authors.lastname: Harvey
authors.forename: B
authors.initials: B
authors.lastname: So
authors.forename: V C
authors.initials: VC
authors.lastname: Dias
mesh_terms: D000236:Adenoma / Q000150:complications / Q000628:therapy*; D000310:Adrenal Gland Neoplasms / Q000150:complications / Q000628:therapy*; D000311:Adrenal Glands / Q000473:pathology* / Q000601:surgery; D000315:Adrenalectomy; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D062865:Diuretics, Potassium Sparing / Q000627:therapeutic use; D005260:Female; D006295:Health Resources / Q000706:statistics & numerical data*; D006801:Humans; D006929:Hyperaldosteronism / Q000209:etiology / Q000628:therapy*; D006965:Hyperplasia / Q000150:complications / Q000628:therapy; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007008:Hypokalemia / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009819:Office Visits / Q000706:statistics & numerical data; D012083:Renin / Q000097:blood; D012189:Retrospective Studies
chemical_list: D000959:Antihypertensive Agents; D062865:Diuretics, Potassium Sparing; D000451:Mineralocorticoid Receptor Antagonists; D000450:Aldosterone; D012083:Renin